- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02281461
Feasibility Study of PrePex Device When Performed on Early Infants & Children Male Population by Physicians (RMC-06)
A Feasibility Study of PrePex Device for Infants and for Children, When Performed on Early Infants and Children Male Population by Physicians
The PrePex is a WHO prequalified medical device for adult male circumcision for HIV prevention. The Government of Rwanda was the first country to implement the PrePex and acts as the leading Center of Excellence providing training and formal guidelines.
In support of efforts to scale up male circumcision, readily available data have been applied to estimate the potential cost and impact of scaling up medical MC services in Rwanda to reach 80 percent of adult, children and newborn males by 2015. Infant and children male circumcision ensures that the wound will be healed before sexual activity begins, and thus reduces the risk of HIV transmission during healing period.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The American Academy of Pediatrics (AAP) published in August 2012 a technical report and a policy statement, "Evaluation of current evidence indicates that the health benefits of new-born male circumcision outweigh the risks; furthermore, the benefits of newborn male circumcision justify access to this procedure for families who choose it. Specific benefits from male circumcision were identified for the prevention of urinary tract infections, acquisition of HIV, transmission of some sexually transmitted infections, and penile cancer. Male circumcision does not appear to adversely affect penile sexual function/sensitivity or sexual satisfaction. It is imperative that those providing circumcision are adequately trained and that both sterile techniques and effective pain management are used. Significant acute complications are rare."
The primary objective of the study was to assess the safety and efficacy of the PrePex device among healthy early infant and children males scheduled for voluntary circumcision. The study consisted of 2 phases:
Phase I included infants age 5-33 days Phase II included children age 4-10 years.
The study examined the feasibility of performing PrePex circumcision on early infants and children male population.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kigali, Rwanda, 0000
- Rwanda Military Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Early infants and children males in ages - 5 to 33 days or 4-10 years
- Weighs more than 2500gr (for early infants)
- The infant or child should be healthy and in full-term
- Parent/legal guardian consent to the circumcision procedure
- Uncircumcised
- Parent/legal guardian able to understand the study procedures and requirements
- Parent/legal guardian agree to keep the infant for 48 hours or child for 24 hours hospitalization
- Parent/legal guardian agree to return to the health care facility for follow-up visits (or as instructed) after his circumcision until complete healing is achieved
- Parent/legal guardian able to comprehend and freely give informed consent for participation in this study and is considered by the investigator to have a good compliance for the study
- Parent/legal guardian agrees to anonymous video and photographs of the procedure and follow up visits.
Exclusion Criteria:
- Parent/legal guardian withhold consent
- Active genital infection, anatomic abnormality or other condition, which in the opinion of the investigator prevents the participant from undergoing a circumcision
- Participant with the following diseases/conditions: Bilateral hydroceles, Curvature with penile torsion, Absence of ventral foreskin, Concealed penis (trapping urine beneath the foreskin), Megalourethra with deficiency of corpus spongiosum, Penoscrotal webbing, Epispadias, dorsal curvature, Hypospadias, Phimosis, paraphimosis, warts under the prepuce, torn or tight frenulum, narrow prepuce, hypospadias, epispadias, known haematological disorders and jaundice, yellow sclera or purpuric skin lesions, congenital abnormality
- Known bleeding / coagulation abnormality, uncontrolled diabetes
- Participant that to the opinion of the investigator is not a good candidate
- Parent/legal guardian does not agree to anonymous video and photographs of the procedure and follow up visits.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Early ifants
Intervention Male circumcision using a non-surgical device
|
Male Circumcision
|
Experimental: Cildren
Intervention Male circumcision using a non-surgical device
|
Male Circumcision
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and efficacy of the PrePex device among early infants and children male population when performed by experienced surgeons
Time Frame: 2 weeks
|
Safety by means of the following parameters: Moderate and Major Clinical adverse events and device-related incidents.
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness of the PrePex device on early infants and children
Time Frame: 2 weeks
|
Glans fully exposed (full circumcision)
|
2 weeks
|
Effectiveness of the PrePex device on early infants and children
Time Frame: 2 weeks
|
Rate of foreskin dilations and adhesion separations
|
2 weeks
|
Effectiveness of the PrePex device on early infants and children
Time Frame: 2 weeks
|
Time to device detachment
|
2 weeks
|
Effectiveness of the PrePex device on early infants and children
Time Frame: 2 weeks
|
Time to complete healing
|
2 weeks
|
Effectiveness of the PrePex device on early infants and children
Time Frame: 2 weeks
|
Rate of expected side effects
|
2 weeks
|
Effectiveness of the PrePex device on early infants and children
Time Frame: 2 weeks
|
Rate of pain / discomfort
|
2 weeks
|
Effectiveness of the PrePex device on early infants and children
Time Frame: 2 weeks
|
Rate of voiding
|
2 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jean Paul Bitega, M.D., Military Insurance, Medical Head of Clinical Affairs
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- RMC-06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Medical Device Complication
-
University Hospital, Basel, SwitzerlandRecruitingMedical Device ComplicationSwitzerland
-
Cairo UniversityUnknownMedical Device Complication
-
University Hospital, Basel, SwitzerlandClinical Trial Unit, University Hospital Basel, SwitzerlandCompletedMedical DeviceSwitzerland
-
Assistance Publique - Hôpitaux de ParisEvolucare Technologies; InES - Innovation Electronic SoftwareUnknown
-
Jun ChoiCompletedMedical DeviceUnited States
-
University of MichiganTerminatedMedical Device | AngiographyUnited States
-
Novo Nordisk A/SCompletedHealthy Volunteers, Medical DeviceNetherlands
-
University of California, San DiegoCompletedMedical Device | Feasibility StudyUnited States
-
Escola Superior de Enfermagem de CoimbraHospital de Braga; Centro Hospitalar e Universitário de Coimbra, E.P.E.; Hospital...UnknownSafety Issues | Medical Device
-
Spartan Bioscience Inc.Ottawa Hospital Research Institute; Children's Hospital of Eastern Ontario; Mount...Completed
Clinical Trials on Male circumcision using a non-surgical device
-
EngenderHealthWeill Medical College of Cornell University; Kenya Ministry of Health; Kenya...CompletedHuman Immunodeficiency VirusKenya
-
University of Illinois at ChicagoNational Institute of Allergy and Infectious Diseases (NIAID); Atma Jaya Catholic...Completed
-
Ministry of Health, RwandaMinistry of Defence, RwandaCompletedHIV Infections | HIV Prevention | Male CircumcisionRwanda
-
University of WashingtonCenters for Disease Control and Prevention; University of Zimbabwe; Ministry... and other collaboratorsCompleted
-
Ministry of Health and Child Welfare, ZimbabweCompleted
-
Ministry of Health, RwandaCompleted
-
FHI 360University of Illinois at Chicago; Bill and Melinda Gates Foundation; Nyanza... and other collaboratorsCompleted
-
University of ThessalyRecruitingPhimosis | Foreskin; Tightness | Redundant PrepuceGreece
-
Simunye Primary Health CareCompleted
-
St. Justine's HospitalFonds de la Recherche en Santé du Québec; Dymedso Inc.; Réseau de Recherche en...UnknownCOVID-19 | Physiotherapy